INCANNEX HEALTHCARE INC.

Highlights Incannex Healthcare Inc.

Equities

IXHL

US45333F1093

Market Closed - Nasdaq Other stock markets 21:30:01 28/05/2024 BST			5-day change	1st Jan Change
2.86 ^USD	+2.88%		+6.72%	-38.36%

05-07	Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	CI
03-05	Incannex Healthcare Inc. Announces CFO Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	05-07	CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	02-28	CI
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	02-16	MT
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	02-16	CI
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-14	CI
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	01-24	CI
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	01-18	CI
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial	01-17	MT
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	01-17	CI
Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia	12-21	CI
Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea	12-06	CI
Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23	CI
Incannex Healthcare Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	27/02/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer